Anti-inflammatory Dietary Intervention in Overweight and Obese Adolescents

Not Applicable

Completed

• Conditions: Obesity; Overweight
• Interventions: Dietary Supplement: Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene; Dietary Supplement: Placebo supplement

• Registration Number: NCT01665742
• Lead Sponsor: University College Dublin

Brief Summary

The number of overweight and obese children has increased in Ireland at a greater rate than worldwide trends. The poor eating patterns that drive adolescent obesity leads to an increase in the number of unhealthy inflammatory hormones and fats circulating in the blood which increase an adolescent's risk of developing diabetes and heart disease later in life. Dietary patterns have changed whereby key nutrients that are found in fruit, vegetables and fish, which are known to have beneficial effects and reduce risk of obesity and diabetes in later life, may need to be replaced. This project will determine whether a key anti-inflammatory nutrient supplement taken for 8 weeks will improve the metabolic profile of adolescents aged 13-18 years old. Detailed cellular analysis will determine the cellular and molecular mechanisms to provide a thorough explanation of the health effects of this intervention.

Detailed Description

The emerging model of obesity and diabetes is characterised by sub-acute chronic inflammation and insulin resistance. Mechanistic data indicates inflamed adipose tissue with increased infiltration of immune cells that generate pro-inflammatory cytokines. With childhood obesity in Ireland increasing at a rapid pace, it is important to establish the role of a non-pharmacological dietary approach to decreasing the sub-acute chronic inflammation seen in overweight and obese children. Several foods contain nutrients that are known to have anti-inflammatory properties. Such foods including fish, fruits and vegetables are known to be deplete in the adolescent diet. The aim of this project is to investigate whether a nutritional supplement containing anti-inflammatory nutrients, n-3 polyunsaturated fatty acids (found in fish oil), vitamin C, vitamin E, and polyphenols found in green tea and tomato; will improve metabolic phenotype in 13-18 year old teenagers over an 8-week period. Further, to provide insight into the role of genetics in the development of metabolic dysregulation and response to dietary treatment.

Study Timeline

• Study Start: 2012-01
• Study First Submitted: 2012-08-12
• Study First Submitted QC: 2012-08-12
• Study First Posted: 2012-08-15
• Primary Completion: 2013-11
• Study Completion: 2013-11
• Status Verified: 2014-12
• Last Update Submitted: 2014-12-05
• Last Update Posted: 2014-12-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

1. Male or female
2. 13-18 years
3. Body mass index ≥ 91st percentile on UK growth reference charts (Cole, 1995)
4. Medications/dietary supplements which do not interfere with the intervention are allowed, on condition that the participants adhere to the same regimen during the intervention, including oral contraceptives and other non-fatty acid based dietary supplements (e.g. garlic)
5. Smoker or non-smoker
6. Not participating in any other intervention study

Exclusion Criteria

1. Pregnancy or lactation
2. Endocrine disorders such as Polycystic Ovary Syndrome
3. Currently on treatment for a chronic inflammatory condition such as asthma
4. Kidney or liver dysfunction
5. Iron deficiency anaemia
6. Prescribed anti-inflammatory medication
7. Consumers of fatty acid supplements including fish oils, evening primrose oil and antioxidant vitamin (A, C, E, -carotene) supplements
8. High consumers of oily fish (> 2 servings/week)
9. Participants planning to start a special diet or lose weight (e.g. Slimfast, Atkins etc)
10. Weight change ≥3kg within the last 3 months
11. Alcohol or drug abuse (based on clinical judgement)
12. Participants with an allergy to fish and/or shellfish

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Anti-inflammatory supplement	Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene	8-weeks of daily supplementation with: 1 x fruit juice fortified with fish oil, and 4 x film-coated tablets containing vitamin C, alpha-tocopherol, green tea extract and lycopene in conjunction with a weight management programme
Placebo supplement	Placebo supplement	8 weeks of daily supplementation with: 1 x fruit juice fortified with high-oleic sunflower oil, and 4 x film-coated placebo tablets in conjunction with a weight management programme

Primary Outcome Measures

Name	Time	Method
Homeostasis model of assessment - insulin resistance	8 weeks	Homeostasis model of assessment - insulin resistance (HOMA-IR) will be derived from fasting glucose and insulin concentrations \[(fasting plasma glucose x fasting serum insulin)/22.5\] as determined by Matthews et al., 1985

Secondary Outcome Measures

Name	Time	Method
Lipid Profile	8 weeks	Full lipid profile and lipidomic analyses (total triacylglycerol, non-esterified fatty acids, total cholesterol, LDL cholesterol, HDL cholesterol and plasma fatty acid composition, diglycerides, cholesterol esters and sphingomyelins,) and related lipid markers
Inflammatory genetic variants	8 weeks	Inflammatory genetic variants such as complement component 3, lymphotoxin- α, IL-6, IL-1β, TNF-α, adiponectin polymorphisms and related variants that link to the inflammatory phenotype
Functional molecular analysis (ex-vivo)	8 weeks	Functional molecular analysis will be conducted to determine which insulin sensitising pathways have been modulated by the intervention
Adiponectin	8 weeks	Adiponectin, a marker of insulin sensitivity, will be determined pre- and post-intervention.
Markers of inflammation	8 weeks	Markers of inflammation such as C reactive protein, interleukin (IL) - 6, IL-1β, tumour necrosis factor alpha, intra-cellular adhesion molecule-1, vascular cell adhesion molecule-1, retinol binding protein 4, fibrinogen, white blood cells and related inflammatory markers

Trial Locations

Locations (3)

Adelaide and Meath Hospital, Incorporating the National Children's Hospital Dublin,; 🇮🇪 Dublin, Ireland

Trinity Centre for Health Sciences, St, James's Hospital; 🇮🇪 Dublin 8, Ireland

University College Dublin; 🇮🇪 Dublin, Ireland